Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
pharmaphorum20h
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...
pharmaphorum1d
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
and have been reaping the rewards of supplying versions of Novo Nordisk's obesity drug Wegovy and Ozempic for diabetes, which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic ...
ncbiotech.org6d
Novo Nordisk Breaks Ground for $1.8B Drug Plant in Clayton
Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there. The ...
Bloomberg L.P.2d
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Yahoo Finance5d
Novo Nordisk A/S (NVO)
After hours: March 14 at 7:59:58 p.m. EDT Loading Chart for NVO ...